14. Aurobindo

2014 Generics Sales: $1.6 billion +75%
Worldwide Market Share: 2.1%

Aurobindo Pharma, which didn't even crack the top 20 in 2013, increased its generics revenue a whopping 75% to $1.6 billion, the largest growth posted by any top 20 company.

The Indian pharma, which specializes in oral and injectable generics, launched several products in the U.S. in 2014, mainly injectables. Its U.S. generics business showed 42% growth, and the company attributes its market expansion to increased penetration of several existing products. The U.S. injectables business grew 88.7% over the previous year's revenues.

It spun off its sterile injectables unit into a separate subsidiary in 2013. And it has been aggressively hunting acquisitions to beef it up, including buying a 60% stake in a new sterile injectable facility that Celon Labs was building for $8 million.

Helping feed that injectable biz, Aurobindo acquired 7 API plants in Western Europe last year from Actavis--now Allergan ($AGN)--which was looking to offload some of the 28 plants it picked up in its acquisition of Watson Pharma. The $41 million deal included products, marketing authorizations and dossier license rights for plants in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands. The company said the deal would give it a "ready-made hospital sales infrastructure for Aurobindo to launch its own injectable and specialty portfolio across Western Europe." It also inked a long-term agreement for Aurobindo to provide APIs to Actavis.

In addition to these steps, Aurobindo planned to expand injectable manufacturing capacity at its existing plants within 18 months to two years. The plants are located near Hyderabad and as of late 2013, they produced $2.5 million to $3 million worth of sterile injectables per month. Managing Director N. Govindarajan said then that he expected this to increase to $8 million to $10 million a month within the next 6 to 8 quarters.

At March 31, 2015, the end of its fiscal year, Aurobindo had filed 376 ANDAs with the FDA. Of these, 193 were approved and 27 more are tentative approvals. -- Amirah Al Idrus (email | Twitter)

For more:
Aurobindo buys supplement maker Natrol out of bankruptcy
Aurobindo deal with Actavis accelerates its expansion of sterile injectables biz

14. Aurobindo

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.